Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 8 of 18
Next
>>
>
176 to 200 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	GDC-0980	3	72	sigmoid	sigmoid	HCC38 apitolisib 0 3 72	8	1.437	0.371	-0.0189	0.29	0.513	-0.179	0.946	0.993	3.35e-07	NA	0.96	0.359	0.808	0.393	0.295	0.998	0.993	3.51e-07	NA
HCC38	Omipalisib	1	72	sigmoid	sigmoid	HCC38 omipalisib 0 1 72	8	1.760	0.0231	-0.316	0.672	0.152	-0.638	0.438	0.97	2.61e-05	NA	0.0585	0.151	0.512	0.0499	0.0356	0.465	0.956	8.65e-05	NA
HCC38	Omipalisib	2	72	sigmoid	sigmoid	HCC38 omipalisib 0 2 72	8	2.124	0.0404	-0.47	0.634	0.45	-1.0	0.456	0.979	9.71e-06	NA	0.0507	0.0595	0.494	0.0507	0.0	0.556	0.96	6.44e-05	NA
HCC38	Omipalisib	3	72	sigmoid	sigmoid	HCC38 omipalisib 0 3 72	8	1.446	0.0145	-0.503	0.802	0.0539	-0.597	0.6	0.993	3.08e-07	NA	0.0449	0.134	0.499	0.0308	0.107	0.644	0.993	2.98e-07	NA
HCC38	KIN001-244	1	72	sigmoid	sigmoid	HCC38 KIN001-244 0 1 72	8	1.751	Inf	0.894	0.0375	4.46	0.77	0.479	0.71	0.0244	NA	Inf	0.909	0.968	4.5	0.802	0.474	0.705	0.0256	NA
BT-549	AZD8055	1	72	sigmoid	sigmoid	BT549 AZD8055 0 1 72	8	1.781	0.0305	0.165	0.526	0.0228	0.14	1.13	0.992	4.7e-07	NA	0.0615	0.382	0.599	0.0189	0.367	1.12	0.994	1.9e-07	NA
HCC38	Buparlisib	1	72	sigmoid	sigmoid	HCC38 buparlisib 0 1 72	8	1.738	0.912	-0.226	0.194	1.46	-0.57	1.62	0.999	9.48e-10	NA	1.2	0.192	0.858	1.12	0.0495	1.66	0.998	4.36e-09	NA
HCC38	Dactolisib	3	72	sigmoid	sigmoid	HCC38 dactolisib 0 3 72	8	1.468	0.0082	-0.197	0.778	0.0127	-0.181	0.711	0.993	3.98e-07	NA	0.0268	0.262	0.497	0.00923	0.277	0.757	0.994	2.62e-07	NA
HCC38	MK2206	2	72	sigmoid	sigmoid	HCC38 MK-2206 0 2 72	8	2.159	Inf	0.788	0.0476	0.776	0.775	1.99	0.972	2.1e-05	NA	Inf	0.785	0.951	0.752	0.772	1.98	0.969	2.9e-05	NA
BT-549	AZD-6482	3	72	sigmoid	sigmoid	BT549 AZD6482 0 3 72	8	1.744	8.87	0.616	0.0979	2.2	0.324	0.749	0.993	2.93e-07	NA	115.0	0.69	0.918	1.91	0.476	0.744	0.993	4.19e-07	NA
HCC38	PI103	1	72	sigmoid	sigmoid	HCC38 PI-103 0 1 72	8	1.782	0.755	0.222	0.201	0.601	0.12	1.2	0.996	4.45e-08	NA	1.39	0.416	0.839	0.494	0.359	1.23	0.995	1.01e-07	NA
HCC38	PI103	2	72	sigmoid	sigmoid	HCC38 PI-103 0 2 72	8	2.094	0.856	0.226	0.167	0.672	0.135	1.3	0.986	2.7e-06	NA	1.04	0.359	0.851	0.488	0.33	1.43	0.981	6.52e-06	NA
HCC38	PI103	3	72	sigmoid	sigmoid	HCC38 PI-103 0 3 72	8	1.481	1.26	0.114	0.168	3.16	-0.762	1.01	0.986	2.53e-06	NA	2.34	0.42	0.884	2.34	0.0	1.03	0.983	4.94e-06	NA
HCC38	PIK-93	1	72	sigmoid	sigmoid	HCC38 PIK-93 0 1 72	8	1.741	5.24	0.61	0.0782	24.5	-1.0	0.713	0.982	6.07e-06	NA	9.93	0.686	0.935	9.93	0.0	0.729	0.979	9.08e-06	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	Dactolisib	2	72	sigmoid	sigmoid	HCC38 dactolisib 0 2 72	8	2.120	0.0118	-0.0557	0.668	0.0118	-0.00134	0.785	0.98	7.61e-06	NA	0.0145	0.204	0.447	0.00701	0.245	0.927	0.988	1.88e-06	NA
HCC38	Dactolisib	1	72	sigmoid	sigmoid	HCC38 dactolisib 0 1 72	8	1.821	0.0109	-0.0403	0.672	0.0104	0.0212	0.892	0.985	3.44e-06	NA	0.0194	0.263	0.492	0.00757	0.301	0.975	0.988	1.65e-06	NA
BT-549	AZD-6482	2	72	sigmoid	sigmoid	BT549 AZD6482 0 2 72	8	1.973	9.15	0.635	0.112	120.0	-1.0	0.426	0.951	0.000115	NA	19.4	0.672	0.895	19.4	0.0	0.437	0.946	0.000154	NA
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
HCC38	AZD8055	3	72	sigmoid	sigmoid	HCC38 AZD8055 0 3 72	8	1.417	0.0464	0.0327	0.53	0.0463	0.000983	1.04	0.997	4.27e-08	NA	0.157	0.392	0.658	0.041	0.372	1.02	0.996	5.78e-08	NA
HCC38	AZD8055	2	72	sigmoid	sigmoid	HCC38 AZD8055 0 2 72	8	2.128	0.0616	0.16	0.467	0.045	0.124	0.912	0.993	3.13e-07	NA	0.0875	0.314	0.594	0.0332	0.284	0.869	0.991	6.5e-07	NA
BT-549	AZD-6482	1	72	sigmoid	sigmoid	BT549 AZD6482 0 1 72	8	1.798	27.5	0.671	0.115	4.1	0.299	0.478	0.992	4.23e-07	NA	164.0	0.723	0.901	4.18	0.408	0.461	0.992	5.34e-07	NA
HCC38	Torin1	1	72	sigmoid	sigmoid	HCC38 Torin1 0 1 72	8	1.688	0.0287	-0.0113	0.569	0.0278	0.013	0.843	0.993	4.14e-07	NA	0.0653	0.304	0.585	0.0204	0.325	0.9	0.992	4.53e-07	NA
BT-20	KIN001-244	2	72	sigmoid	sigmoid	BT20 KIN001-244 0 2 72	8	1.742	Inf	0.85	0.0644	4.47	0.713	0.316	0.721	0.0218	NA	Inf	0.873	0.945	4.51	0.757	0.309	0.715	0.0231	NA
BT-20	Alpelisib	1	72	sigmoid	sigmoid	BT20 alpelisib 0 1 72	8	2.077	1.14	0.046	0.196	3.52	-1.0	0.977	0.966	4.1e-05	NA	1.32	0.26	0.825	1.32	0.0	1.13	0.942	0.000194	NA

|<
<<
Previous
Page 8 of 18
Next
>>
>
176 to 200 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)